Results 181 to 190 of about 5,310 (212)
Some of the next articles are maybe not open access.
The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics
Pharmacogenomics, 2002Thiopurine methyltransferase catalyzes the S-methylation of azathioprine (AZA), 6-mercapto-purine (6-MP) and thioguanine, medications widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease and solid organ transplant rejection.
Howard L, McLeod, Chokkalingam, Siva
openaire +2 more sources
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
Pharmacogenetics and Genomics, 2005Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs. Genetic polymorphisms for TPMT are a major factor responsible for large individual variations in thiopurine toxicity and therapeutic effect. The present study investigated the functional effects of human TPMT variant alleles that alter the encoded amino acid sequence
Oreste E, Salavaggione +4 more
openaire +2 more sources
Thiopurine S-Methyltransferase Pharmacogenetics in Childhood Acute Lymphoblastic Leukemia
2013Pharmacogenetics is the growing field of study of genetic variations underlying interindividual differences in drug response. Inherited polymorphisms in genes coding for drug-metabolizing enzymes, transporters, and targets influence toxicity as well as efficacy associated with the medication.
Jun J, Yang, Deepa, Bhojwani
openaire +2 more sources
Cat Red Blood Cell Thiopurine S-Methyltransferase: Companion Animal Pharmacogenetics
The Journal of Pharmacology and Experimental Therapeutics, 2004A common genetic polymorphism for thiopurine S-methyltransferase (TPMT) is a major factor responsible for individual variation in the toxicity and therapeutic efficacy of thiopurine drugs in humans. We set out to determine whether inheritance might also influence the level of TPMT activity in the domestic cat, Felis domesticus.
Oreste E, Salavaggione +6 more
openaire +2 more sources
Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism, 2012Thiopurine S-methyltransferase (TPMT) catalyzes the methylation of thiopurine drugs, such as azathioprine and mercaptopurine, which are used in a variety of diseases. Several mutations in the TPMT gene correlate with low enzyme activity and subsequent adverse effects, mainly myelotoxicity.
Teresa, Cabaleiro +3 more
openaire +2 more sources
Identification of a novel thiopurine S-methyltransferase allele (TPMT*37)
Pharmacogenetics and Genomics, 2014Thiopurine S-methyltransferase (TPMT) is a key enzyme in the methylation of the thiopurine drugs azathioprine and 6-mercaptopurine. TPMT is subject to genetic polymorphism that results in a trimodal distribution of enzyme activity. All poor methylators (PMs) and 30-60% of intermediate methylators develop potentially life-threatening myelosuppression on
Rebecca L, Roberts +3 more
openaire +2 more sources
Azathioprine, 6‐mercaptopurine and thiopurine S‐methyltransferase
Journal of Gastroenterology and Hepatology, 2005I C, Roberts-Thomson, W J, Butler
openaire +2 more sources
Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency
Annals of Internal Medicine, 1997Eugene Y. Krynetski, William E. Evans
openaire +2 more sources
Thiopurine S-methyltransferase gene polymorphism in pemphigus vulgaris
2019Introduction: Thiopurine S-methyltransferase (TPMT) genotypes or phenotypes are important as a predictive factor for thiopurine-induced toxicity. Individuals who are TPMT deficient or have intermediate TPMT activity are at risk of developing myelosuppression and life-threatening leucopenia when treated with standard doses of thiopurines; thus ...
Genc A. +4 more
openaire +1 more source